Neogen Corp

Neogen Corp(NEOG)股票分析

$11.660

-0.079 (-0.68%)收盤時

Loading chart…
High
11.790
Open
11.740
VWAP
11.63
Vol
1.31M
Mkt Cap
3.46B
Low
11.430
Amount
15.20M
EV/EBITDA, TTM
24.71

Neogen Corporation and subsidiaries are engaged in developing, manufacturing and marketing a diverse line of products and services dedicated to food and animal safety. The Company has developed comprehensive solutions spanning the Food Safety, Livestock, and Pet Health & Wellness markets. Its segments include Food Safety and Animal Safety. The Food Safety segment is primarily engaged in the development, production and marketing of diagnostic test kits and related products used by food producers and processors to detect harmful natural toxins, foodborne bacteria, allergens and levels of general sanitation. The Animal Safety segment is primarily engaged in the development, production and marketing of products dedicated to animal safety, including a complete line of consumable products marketed to veterinarians and animal health product distributors. This segment also provides genomic identification and related interpretive bioinformatic services.

AI analysis of Neogen Corp (NEOG)

buy

Neogen Corp is a good buy right now due to its current price of $11.66 being below the analyst target of $14, indicating a potential upside of 20.3%. Additionally, the company has shown significant improvement in financial performance, with a reduction in net loss to $11.3 million in Q4, compared to a loss of $612.2 million in the previous year. The main risk is the forward P/E ratio of 16, which suggests that while the stock is currently undervalued, it may face challenges in maintaining growth expectations.

Analyst Ratings (7)

-29.93% downside
Hold
0 Buy
7 Hold
0 Sell
Current: 11.66
最低
6.50
平均
8.17
最高
10.00

Piper Sandler

2026-08-26

目標價

$14

Overweight

Piper Sandler

2026-08-03

目標價

$13

Neutral

Guggenheim

2026-01-09

目標價

$12

Buy

CJS Securities

2025-12-10

目標價

$10

Outperform

Piper Sandler

2025-10-16

目標價

$5

Neutral

估值指標

The current forward P/E ratio for Neogen Corp (NEOG) is 16.00, compared to its 5-year average forward P/E of 32.68.

Forward P/E

Undervalued
5Y Average P/E
32.68
Current P/E
16.00
高估
48.80
低估
16.55

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
17.03
Current EV/EBITDA
24.71
高估
26.09
低估
7.98

Forward P/S

Fair
5Y Average P/S
3.75
Current P/S
2.96
高估
5.64
低估
1.87

Alphio AI Price Scenarios for NEOG

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%NEOG

$7.55

情境價格

B

Base

Base · 50%NEOG

$6.69

情境價格

B

Bear

Bear · 25%NEOG

$6.11

情境價格

Whales holding NEOG

G

Gates Capital Management, Inc.

+ HoldingNEOG

-1.91%

3M Return

事件時間軸

2026-08-19 (ET)

17:00:00

Sera Prognostics Appoints Scott Gleason as CFO

2026-06-18 (ET)

09:00:00

Neogen Expands Availability of Prozap Products

2026-04-23 (ET)

09:00:00

Neogen Receives Certification for Listeria Detection Test

2026-04-09 (ET)

16:10:00

Major Averages Close Higher as Oil Prices Rise 5%

12:00:00

Major Averages Rise as Oil Prices Surpass $100

資訊

NEOG FAQ — answered by Alphio AI

Neogen Corporation and subsidiaries are engaged in developing, manufacturing and marketing a diverse line of products and services dedicated to food and animal safety. The Company has developed comprehensive solutions spanning the Food Safety, Livestock, and Pet Health & Wellness markets. Its segments include Food Safety and Animal Safety. The Food Safety segment is primarily engaged in the development, production and marketing of diagnostic test kits and related products used by food producers and processors to detect harmful natural toxins, foodborne bacteria, allergens and levels of general sanitation. The Animal Safety segment is primarily engaged in the development, production and marketing of products dedicated to animal safety, including a complete line of consumable products marketed to veterinarians and animal health product distributors. This segment also provides genomic identification and related interpretive bioinformatic services. It operates in the Healthcare sector (IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES industry).

Neogen Corp is a good buy right now due to its current price of $11.66 being below the analyst target of $14, indicating a potential upside of 20.3%. Additionally, the company has shown significant improvement in financial performance, with a reduction in net loss to $11.3 million in Q4, compared to a loss of $612.2 million in the previous year. The main risk is the forward P/E ratio of 16, which suggests that while the stock is currently undervalued, it may face challenges in maintaining growth expectations.

7 analysts cover NEOG: 0 rate it Buy, 7 Hold and 0 Sell. The average price target is 8.17.

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

免費開始